Nervous system

Orphan designation: Adeno-associated viral vector containing porphobilinogen deaminase gene Treatment of acute intermittent porphyria, 29/04/2009 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Community, Eurostat, Civil service commission, Depression, Diagnosis, Psychosis, Cell, Disease, Seizure, Nervous system, Patient, Committee, Knowledge, Light, Regulation, Anxiety, Liver transplantation, EMA, IRIS, AIP, Human, Urine, European, Skin, COMP, Oxygen, Porphyria, European Commission, Safety, Blood, Marketing, Liver, DSM-IV codes, Medicine, Pharmaceutical industry

Orphan designation: Adeno-associated viral vector containing porphobilinogen deaminase gene Treatment of acute intermittent porphyria, 29/04/2009 Withdrawn

Key Points: 


Orphan designation: Adeno-associated viral vector containing porphobilinogen deaminase gene Treatment of acute intermittent porphyria, 29/04/2009 Withdrawn

 Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024

Retrieved on: 
Wednesday, March 20, 2024
Nervous system, Telehealth, Health, AMIX, AI

THE WOODLANDS, TX, March 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, announced today that Lori Bisson, Chief Executive Officer of Autonomix will present at the Benzinga Virtual Healthcare Summit 2024 on Wednesday, March 20, 2024 at 11:50 AM ET.

Key Points: 
  • Live webcast presentation on Wednesday, March 20th at 11:50 AM ET
    THE WOODLANDS, TX, March 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, announced today that Lori Bisson, Chief Executive Officer of Autonomix will present at the Benzinga Virtual Healthcare Summit 2024 on Wednesday, March 20, 2024 at 11:50 AM ET.
  • Benzinga's Virtual Healthcare Summit is a virtual event where the brightest minds in healthcare, influential companies, analysts, and thought leaders converge to shape the future of health.
  • Join the event for a dynamic exploration of the healthcare and biotech landscape, covering topics including AI, telemedicine, oncology, medical devices, healthcare M&A activity, and the latest start-ups.

Autonomix Appoints Jennifer Cook as Chief Business Officer

Retrieved on: 
Tuesday, March 19, 2024
AbbVie, Growth, Health, Miami University, Real Chemistry, Nervous system, Business administration, Integration, Adjustable gastric band, Research, Class, Marketing communications, Jennifer Cook, Electrophysiology, Record, Translation, Marketing, Cellulite, Advertising, AMIX, Management

THE WOODLANDS, TX, March 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Jennifer Cook as its Chief Business Officer.

Key Points: 
  • Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated companies.
  • “We are very pleased to welcome Jennifer to the Autonomix team.
  • Her expertise in business strategy and analysis will be of great value as we continue to execute on our corporate and clinical efforts moving forward.
  • Mrs. Cook holds a Bachelor of Science in Business Administration and Marketing from Miami University, Oxford, Ohio.

NXP Collaborates with NVIDIA to Accelerate AI Deployment with Integration of TAO Toolkit with NXP Edge Devices

Retrieved on: 
Monday, March 18, 2024
NXP Semiconductors, Algorithm, Nervous system, Environment, Internet of things, Library, AI, Software, Primary energy, Senior, TAO, NPU, API, NXP, Machine learning, Collection, NXPI, NVIDIA, Video game

This exciting enablement offers developers the ability to accelerate development in the increasingly competitive world of AI, made possible by the functional integration of the NVIDIA TAO Toolkit into the NXP’s eIQ machine learning development environment .

Key Points: 
  • This exciting enablement offers developers the ability to accelerate development in the increasingly competitive world of AI, made possible by the functional integration of the NVIDIA TAO Toolkit into the NXP’s eIQ machine learning development environment .
  • NXP is the first semiconductor vendor to integrate the NVIDIA TAO APIs directly within an AI enablement offering to make it easier for developers to deploy trained AI models at the edge.
  • Simplifying the training and deployment of AI models is one of the biggest challenges facing today’s AI developers.
  • To address this challenge, NXP collaborated with NVIDIA to integrate the NVIDIA TAO APIs directly within NXP’s eIQ machine learning development environment.

Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Retrieved on: 
Thursday, March 14, 2024
Principal, Ethanol, Collateral damage, Disease, Nervous system, Patient, POC, Pancreatic cancer, Clinical trial, Pain, AMIX, Medical imaging

THE WOODLANDS, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the safe completion of the first three patient procedures for its proof-of-concept (PoC) human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • “We are pleased to have safely completed the first patient procedures utilizing RF ablation in a transvascular approach to reduce the pain associated with pancreatic cancer.
  • The Principal Investigator was able to navigate the catheter to the target treatment area and perform the specified ablations with no significant adverse events.
  • The primary objective of the PoC human clinical trial is to successfully ablate relevant somatic nerves and mitigate pain in patients with pancreatic cancer pain utilizing RF ablation in a transvascular approach to the nerves in the region.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the trial.

Revive Therapeutics Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
DRDC, Neuroprotection, Tremor, Diazepam, Chronic pain, COVID, Soman, National security, Survival, NAC, Seizure, Partnership, Nervous system, VX, COVID-19, Nerve agent, Patient, Brain, Heart rate, Research, Diarrhea, Endocytosis, RVV, Death, Doctor of Philosophy, Health Canada, Trial of the century, Cough, Traumatic brain injury, CDC, Harvard University, Fever, Sarin, Bleeding, Safety, Chemical warfare, Saliva, Therapy, Disorder, Blurred vision, FDA, Economics, Nerve, Hospital, Pharmaceutical industry

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.

Key Points: 
  • TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.
  • Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.
  • In addition, Revive may evaluate the potential of its proposed long COVID diagnostic product as a companion to Bucillamine.
  • The Company, under its wholly-owned subsidiary Revive Diagnostics Inc., is advancing the product development of a potential blood biomarker diagnostic that characterizes long COVID.

Bioelectronic medicine Feinstein Institutes researchers elected to AIMBE College of Fellows

Retrieved on: 
Monday, March 25, 2024
Health, Health Insurance, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Vagus nerve, Metabolism, Interdisciplinarity, Biomedical engineering, Brain, Sepsis, Rheumatoid arthritis, Medicine, Mevalonate pathway, Interface (computing), Communication, International Society, Disease, Paralysis, Diabetes, Education, Inflammation, Pulmonary hypertension, Nervous system, Class, PNAS, Cancer, Neuroscience, Doctor of Philosophy, AIMBE, Neuron, Inflammatory Bowel Diseases, Arthritis, Credit, Northwell Health, American Institute, Molecular medicine, Sensation, Infection, DRS, Immune system, Injury, Medical research, Inflammatory bowel disease, Biology, Multimedia, National academy, Government, ISAN, Medical device

The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.

Key Points: 
  • The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.
  • Valentin Pavlov, PhD , and Sangeeta Chavan, PhD , both professors in the Institute of Bioelectronic Medicine , were recognized in-person during the AIMBE Annual Event in Washington D.C..
  • Sangeeta Chavan (left) and Valentin Pavlov (right) have been elected to the AIMBE College of Fellows for advancing the fields of medical and biological engineering.
  • On behalf of the Feinstein Institutes and Northwell Health, we congratulate them.”
    The Feinstein Institutes for Medical Research is the global scientific home of bioelectronic medicine where medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Dr. Mark Silver Offers Options to Avoid Back Surgery

Retrieved on: 
Friday, March 22, 2024
General Health, Health, Surgery, Neurology, Nervous system, Nerve, Pain, Patient, Neurosurgery, Brain, Spinal cord stimulator, Diabetic neuropathy, Back pain, Dentistry

Dr. Mark Silver , founder of the Silver Spine and Neurological Center , offers treatments that can help many patients avoid the need for surgery to address back pain.

Key Points: 
  • Dr. Mark Silver , founder of the Silver Spine and Neurological Center , offers treatments that can help many patients avoid the need for surgery to address back pain.
  • “Surgery can be an effective form of back pain management,” said Dr. Mark Silver.
  • “But there are many other treatments that can avoid the need for surgery and should be considered.”
    Dr. Mark Silver is an expert on Neuromodulation, techniques that act directly on the nervous system.
  • By changing the way a patient’s nerves carry information to and from the brain, pain can be decreased and mobility improved.

Implantable Brain-Computer Interface Collaborative Community (iBCI-CC) to Drive Innovation in Neurotechnology

Retrieved on: 
Monday, March 11, 2024
Research, Other Health, Medical Devices, Hospitals, Health Technology, Surgery, Clinical Trials, Science, Neurology, Biotechnology, FDA, Health, Other Science, Device, DSM-IV codes, Harvard Medical School, BCI, Organization, Mass General Brigham, CDRH, Communication, Massachusetts General Hospital, ALS, Nervous system, Patient, Neurotechnology, Jennifer French, Neuroscience, Friends, Software, Doctor of Philosophy, Master of Science, MBA, Hospital, Physical disability, Safety, Ecosystem, Family, Mass, Food

Mass General Brigham is establishing the Implantable Brain-Computer Interface Collaborative Community (iBCI-CC).

Key Points: 
  • Mass General Brigham is establishing the Implantable Brain-Computer Interface Collaborative Community (iBCI-CC).
  • This is the first Collaborative Community in the clinical neurosciences that has participation from the U.S. Food and Drug Administration (FDA).
  • BCIs are devices that interface with the nervous system and use software to interpret neural activity.
  • This collaborative effort aims to propel the field of iBCIs forward by employing harmonized approaches that drive continuous innovation and ensure equitable access to these transformative technologies.

IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis

Retrieved on: 
Thursday, April 4, 2024
Vital capacity, MuSK protein, Glucocorticoid, NMPA, Hormone, GMG, Disease, Chinese, MRS, BCMA, Nervous system, Patient, SAN, Enzyme inhibitor, History, Female, Multiple myeloma, CRS, B cell, Biotechnology, IND, Phenotype, Investigational New Drug, QMG, Safety, Thymectomy, FDA, Food

The Chinese IND for this indication of Equecabtagene Autoleucel was approved by the NMPA in January this year.

Key Points: 
  • The Chinese IND for this indication of Equecabtagene Autoleucel was approved by the NMPA in January this year.
  • The 2 subjects were treated with a single infusion of Eque-cel at the doses of 1.0×106 CAR-T/Kg, respectively.
  • No immunomodulatory therapy other than low dose pyridostigmine (90 mg/day and 60 mg/day, respectively) was used during the follow-up period.
  • Anti-AChR antibodies, anti-Titin antibodies, and anti-MuSK antibodies decreased rapidly and maintained at very low levels in both subjects after infusion.